Cometriq

Progressive, metastatic medullary thyroid cancer. Note: Cabometyx (tablets) is the formulation for RCC and HCC.

140 mg orally once daily on empty stomach.

Capsules: 20 mg, 80 mg

None listed in the prescribing information.

• Hemorrhage: Severe and fatal hemorrhages reported.
• GI Perforations/Fistulas: Monitor and discontinue if perforation occurs.
• Thrombotic Events: Arterial and venous thromboembolism reported.
• Hypertension: Monitor and manage.
• PPES: Dose reduction may be required.
• Embryo-Fetal Toxicity: Can cause fetal harm.

Diarrhea (63%), Stomatitis (51%), PPES (50%), Weight Loss (48%), Decreased Appetite (46%), Nausea (43%), Fatigue (41%), Dysgeusia (34%), Hypertension (33%)

Consult the complete prescribing information for a comprehensive list of adverse reactions and their frequencies.

Strong CYP3A4 Inhibitors: Reduce dose by 40 mg daily.
Strong CYP3A4 Inducers: Increase dose by 40 mg daily (max 180 mg).

Consult the full prescribing information for pregnancy-related considerations.

Refer to prescribing information for lactation guidance.

Pediatric safety and efficacy information is detailed in the full label.

Dose modifications for organ impairment are specified in the complete prescribing information.

Cabozantinib inhibits MET, VEGFR-1/2/3, RET, KIT, AXL, FLT3, and TIE2. In medullary thyroid cancer, RET mutations drive tumor growth; cabozantinib blocks these pathways.

Tmax: 2-5 hours. Protein binding: >=99.7%. Half-life: ~55 hours. Elimination: feces 54%, urine 27%.

Clinical efficacy and safety data supporting the approval are available in the full prescribing information and from the clinical trials listed below.

• EXAM — Cabozantinib vs placebo in progressive MTC. Phase III, n=330.
  🔬 NCT00704730 ↗ 📄 Primary Publication ↗

Cometriq has FDA-approved indications across the following cancer types covered on CancerDrugEvidence: